Also known as: Gattex
A GLP-2 analog for short bowel syndrome.
Educational reference, not medical advice. Many compounds here are not approved, and products sold as research chemicals are not checked for purity. Plan any use with a licensed clinician.
How it works
Grows the absorptive lining of the intestine, so patients need less IV nutrition.
Evidence by goal
| Goal | Grade | What the grade means |
|---|---|---|
| Gut health | A | Approved for this use or large randomized trials |
At a glance
- Route
- Subcutaneous daily
- Half-life
- About 2 hours
Reported dosing
0.05 mg/kg once daily.
Timing: Once daily, any time.
Cycle: Ongoing, with regular colonoscopy.
From approved labels where they exist, otherwise from published trials and practitioner reports.
Side effects
- Abdominal pain, swelling at stoma
- Risk of intestinal polyps and growth of existing tumors
Who should avoid it
- Active GI cancer
Often combined with
Alone.
Key findings
Reduced need for parenteral nutrition by 20% or more in most trial patients.
Where it is legal (Oct 2026)
| US | Prescription |
|---|---|
| Canada | Prescription |
| Mexico | Verify locally |
| EU | Prescription |
Sources
Open Teduglutide in the Peptide Guide Compare all peptides by goal
Last reviewed November 2026. Regulatory status reflects the US unless noted and changes often.